Project Grant R00CA263194
Award Date
8/1/24
Completion Date
7/31/27
Dollars Obligated
$249K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $465,404 to Case Western Reserve University to conduct research on the role of the protein Cyclin D1 and its regulation by the FBXO4 E3 ligase in head and neck squamous cell carcinoma (HNSCC). The key objectives are to: 1) Determine if a specific p53 mutation can cooperate with a Cyclin D1 mutation to drive HNSCC development in vivo; 2) Elucidate the mechanisms by which...
The Case Western Reserve University will receive $1,168,656 in funding from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to support the project "FADD: A MECHANISTIC BASIS AND THERAPEUTIC OPPORTUNITY FOR OVERCOMING CDK4/6 INHIBITOR RESISTANCE" from April 1, 2023 to March 31, 2026. Through this three-year Project Grant, Case Western Reserve University researchers will investigate mechanisms of resistance to...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) program provides $693,134 to Case Western Reserve University (CWRU) to elucidate the molecular details of EPHA1 homo-dimerization and EPHA1-EPHA2 hetero-interactions, and to delineate their roles in EPHA1 and EPHA2 signaling and functions. The overarching goal is to add novel knowledge to the understanding of EPHA1 and EPHA2 in human cancers, including hepatocellular carcinoma, and...
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, supports research on the role of histone cleavage in breast cancer. The $170,640 award to the Dana-Farber Cancer Institute aims to investigate how the histone demethylase KDM4C drives tumor growth by preventing proteolytic cleavage of the histone H3 N-terminal tail by cathepsin L. The project will generate and characterize cell models to study this...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports a research project at the University of Miami aimed at improving the survival rate of patients with metastatic, endocrine-resistant breast cancer. The $447,340 award, effective March 1, 2025 through February 28, 2030, will fund research to identify epigenetic vulnerabilities and therapeutic targets in breast cancer cells that have developed resistance to endocrine therapy. Specifically,...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) will provide $606,869 to Case Western Reserve University from July 2024 through June 2029 to study the mechanisms of androgen receptor inverse agonists in treating advanced prostate cancer. The research aims to map the epigenetic mechanisms driving treatment-resistant metastatic castration-resistant prostate cancer, and to develop novel small molecule therapies that can functionally...
The National Cancer Institute (NCI) awarded a $340,072 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The grant, awarded on September 20, 2024, supports research to evaluate TMU27A, a novel non-nucleoside ribonucleotide reductase (RNR) inhibitor, as a potential treatment for metastatic breast cancer. The proposed studies will investigate TMU27A's impact on genome stability, efficacy,...
This $590,625 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel therapeutic strategy targeting mutant p53 in triple negative breast cancer (TNBC). The key products and services to be delivered under this 5-year grant include: Determining how the CDK4/6-RBM38-eIF4G axis regulates mutant p53 expression and the role of mutant p53 as a target of CDK4/6 inhibitors in suppressing mutant p53-expressing TNBCs. Evaluating...
The federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $647,118 to the University of Colorado-Denver to study the role of the EYA3/PP2A pathway in regulating triple negative breast cancer (TNBC) metastasis. The research aims to determine the molecular and cellular mechanisms by which the EYA3-NF-κB axis enhances TNBC metastasis, and to understand how EYA3 regulates NF-κB signaling through its interaction with the PP2A-B55α subunit. The...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $391,531 to Yale University to develop technology for directing phosphorylation of specific protein kinase substrates. The goal is to engineer a kinase mutant that can selectively phosphorylate a designer allele of one of its substrates, using knowledge of kinase phosphorylation site specificity. The researchers will establish the feasibility of this approach using the tumor...